Ashley Margol

Dr. Ashley Margol


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Cancer Genetics
Verified
Journal Article
Closed access
AMAshley Margol
Ashley Margol
AJAlexander R. Judkins
Alexander R. Judkins

1 June 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MNMichael Neely
Michael Neely
AMAshley Margol
Ashley Margol
XFXiaowei Fu
Xiaowei Fu
MGMichael van Guilder
Michael van Guilder
DBDavid Bayard
David Bayard
WHWilliam Hope
William Hope
Despite the documented benefit of voriconazole therapeutic drug monitoring, nonlinear pharmacokinetics make the timing of steady-state trough sampling and appropriate dose adjustments unpredictable by conventional methods. We developed a nonparametric population model with data from 141 previously richly sampled children and adults. We then used it in our multiple-model Bayesian adaptive control algorithm to predict measured concentrations and doses in a separate cohort of 33 pediatric patients aged 8 months to 17 years who were receiving voriconazole and enrolled in a pharmacokinetic study. Using all available samples to estimate the individual Bayesian posterior parameter values, the median percent prediction bias relative to a measured target trough concentration in the patients was 1.1% (interquartile range, −17.1 to 10%). Compared to the actual dose that resulted in the target concentration, the percent bias of the predicted dose was −0.7% (interquartile range, −7 to 20%). Using only trough concentrations to generate the Bayesian posterior parameter values, the target bias was 6.4% (interquartile range, −1.4 to 14.7%; P = 0.16 versus the full posterior parameter value) and the dose bias was −6.7% (interquartile range, −18.7 to 2.4%; P = 0.15). Use of a sample collected at an optimal time of 4 h after a dose, in addition to the trough concentration, resulted in a nonsignificantly improved target bias of 3.8% (interquartile range, −13.1 to 18%; P = 0.32) and a dose bias of −3.5% (interquartile range, −18 to 14%; P = 0.33). With the nonparametric population model and trough concentrations, our control algorithm can accurately manage voriconazole therapy in children independently of steady-state conditions, and it is generalizable to any drug with a nonparametric pharmacokinetic model. (This study has been registered at ClinicalTrials.gov under registration no. NCT01976078.)

11 September 2014 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JXJingying Xu
Jingying Xu
AMAshley Margol
Ashley Margol
SAShahab Asgharzadeh
Shahab Asgharzadeh
AEAnat Erdreich-Epstein
Anat Erdreich-Epstein

9 April 2022 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
TRTom Rosenberg
Tom Rosenberg
KYKee Kiat Yeo
Kee Kiat Yeo
AMAudrey Mauguen
Audrey Mauguen
SASanda Alexandrescu
Sanda Alexandrescu
SPSanjay P Prabhu
Sanjay P Prabhu
MKMatthias A Karajannis
Matthias A Karajannis
The prognosis for patients with pediatric high-grade glioma (pHGG) is poor despite aggressive multimodal therapy. Objective responses to targeted therapy with BRAF inhibitors have been reported in some patients with recurrent BRAF-mutant pHGG but are rarely sustained. We performed a retrospective, multi-institutional review of patients with BRAF-mutant pHGG treated with off-label BRAF +/– MEK inhibitors as part of their initial therapy. Nineteen patients were identified, with a median age of 11.7 years (range, 2.3–21.4). Histologic diagnoses included HGG (n = 6), glioblastoma (n = 3), anaplastic ganglioglioma (n = 4), diffuse midline glioma (n = 3), high-grade neuroepithelial tumor (n = 1), anaplastic astrocytoma (n = 1), and anaplastic astroblastoma (n = 1). Recurrent concomitant oncogenic alterations included CDKN2A/B loss, H3 K27M, as well as mutations in ATRX, EGFR, and TERT. Eight patients received BRAF inhibitor monotherapy. Eleven patients received combination therapy with BRAF and MEK inhibitors. Most patients tolerated long-term treatment well with no grade 4–5 toxicities. Objective and durable imaging responses were seen in the majority of patients with measurable disease. At a median follow-up of 2.3 years (range, 0.3–6.5), three-year progression-free and overall survival for the cohort were 65% and 82%, respectively, and superior to a historical control cohort of BRAF-mutant pHGG patients treated with conventional therapies. Upfront targeted therapy for patients with BRAF-mutant pHGG is feasible and effective, with superior clinical outcomes compared to historical data. This promising treatment paradigm is currently being evaluated prospectively in the Children’s Oncology Group ACNS1723 clinical trial.

12 April 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
TFTaryn B. Fay-McClymont
Taryn B. Fay-McClymont
DPDanielle M. Ploetz
Danielle M. Ploetz
DMDon Mabbott
Don Mabbott
KWKarin Walsh
Karin Walsh
ASAmy Smith
Amy Smith
LLLucie Lafay-cousin
Lucie Lafay-cousin

9 February 2023 in Neoplasia
Verified
Journal Article
Open access
EAElizabeth Alva
Elizabeth Alva
JRJeffrey Rubens
Jeffrey Rubens
SCSusan Chi
Susan Chi
TRTom Rosenberg
Tom Rosenberg
ARAlyssa Reddy
Alyssa Reddy
AMAshley Margol
Ashley Margol
Atypical teratoid rhabdoid tumors (AT/RT) are malignant central nervous system (CNS) tumors that occur mostly in young children and have historically carried a very poor prognosis. While recent clinical trial results show that this tumor is curable, outcomes are still poor compared to other central nervous system embryonal tumors. We here review prior AT/RT clinical trials and highlight promising pre-clinical results that may inform novel clinical approaches to this aggressive cancer.